First Opinion By James R. Baker Jr. EpiPen pricing controversy reflects larger issues in pharma industry
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Most Californians support proposed law to limit drug prices
The Pharmalot View By Ed Silverman Behind the grandstanding, Congress may have taken a key step to clarifying drug prices
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Mylan’s parent bloggers feel jilted thanks to price hikes
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Congress probes FDA’s Office of Criminal Investigations
Pharmalot By Ed Silverman California governor decries ‘predatory’ pricing as he signs law to make EpiPen available
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Mylan quietly pushes effort to blunt impact of EpiPen pricing
Pharmalot By Ed Silverman Bipartisan bill in Congress would require drug makers to justify, limit price hikes
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Mylan CEO to testify about EpiPen before Congress next week
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Teva expects FDA to speed review of its generic EpiPen
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Are concerns about spending on orphan drugs overblown?
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Immunotherapy is complicating clinical trial designs
Pharmalot By Ed Silverman Q&A: Allergan’s CEO speaks out on limiting drug prices. ‘Somebody had to take the first step’
Pharmalot By Ed Silverman Allergan CEO promises to limit price hikes on drugs in a bid to rebuild the ‘social contract’
Pharmalot By Ed Silverman Anyone see the rebates? Lawmakers accuse Mylan of underpaying Medicaid for EpiPen